Cardinal Health price target raised to $52 from $50 at RW Baird Baird raised its price target on Cardinal Health following Q1 results. The firm cited earnings leverage, continued generics contributions, growth in platforms outside of drug distribution, and share repurchases. Shares are Outperform rated.
News For CAH From The Last 14 Days
Check below for free stories on CAH the last two weeks.